Ketogenic Diet: a Novel Metabolic Strategy to Treat Lymphedema Patients? (KETOLYMPH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03991897|
Recruitment Status : Recruiting
First Posted : June 19, 2019
Last Update Posted : November 17, 2020
Lymphedema is a debilitating disorder that severely impairs the quality of life of the patients and requires life-long attention. Treatment for lymphatic dysfunction remains largely symptomatic, without real cure. According to the International Society of Lymphology, lymphedema has to be treated with Decongestive Lymphatic Therapy.
Research in the lab of Angiogenesis and Vascular Metabolism (PCA lab) reported in mice that metabolism of endothelial cells controls vessel sprouting. Experiments showed that a ketogenic diet (KD) reduced the edema of the mice tail and enhanced the lymphatic transport. Based on these proof-of-concept data, the investigators plan to test this innovative concept to ameliorate lymph vessel dysfunction in lymphedema patients. Randomisation will be performed between a ketogenic diet and a isocaloric diet.
|Condition or disease||Intervention/treatment||Phase|
|Lymphedema Ketogenic Dieting||Dietary Supplement: Ketogenic diet Dietary Supplement: Isocaloric diet||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
After baseline assessment, patients will be randomized in one of the treatment groups.
Randomization is performed according to 'www.randomization.com'. This free generator randomizes each subject to a single treatment by using the method of randomly permuted blocks.
Assessments are performed by a person blinded to the treatment allocation groups.
Randomization will be stratified for baseline lymphedema volume (3-9.9%, 10.0-19.9% and ≥20%), affected limb (arm or leg) and gender (females or males). The staff members who perform the measurements are blinded for the allocation.
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||The staff members who perform the measurements are blinded for the allocation.|
|Official Title:||Ketogenic Diet: a Novel Metabolic Strategy to Treat Lymphedema Patients?|
|Actual Study Start Date :||May 13, 2019|
|Estimated Primary Completion Date :||January 7, 2023|
|Estimated Study Completion Date :||January 7, 2023|
Experimental: Ketogenic diet
the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.
Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not.
Dietary Supplement: Ketogenic diet
Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
Active Comparator: Isocaloric diet
During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
Dietary Supplement: Isocaloric diet
Patients will follow an isocaloric diet
- Change in edema volume at 24 weeks [ Time Frame: up to 24 weeks ]measured with volumeter
- Change in edema volume at 24 weeks [ Time Frame: up to 24 weeks ]Measured with tape circumference
- Change in lymphatic transport [ Time Frame: up to 48 weeks ]measured by lymphofluoroscopy
- Change in lymphatic transport [ Time Frame: up to 48 weeks ]Measured with lymphoscintigraphy
- Change in edema volume at 12 and 48 weeks [ Time Frame: up to 48 weeks ]measured with volumeter
- Change in edema volume at 12 and 48 weeks [ Time Frame: up to 48 weeks ]measured with tape circumference
- Changed extracellular volume [ Time Frame: up to 48 weeks ]measured with BioImpedance Spectroscopy
- Changed quality of life [ Time Frame: up to 48 weeks ]measured with QOL questionnaire, a scale from 0-10 on 16 items, how higher the score, how higher the QOL
- Changed quality of life [ Time Frame: up to 48 weeks ]measured with Lymph ICF (international classification of functioning, disability and Health), a scale from 0-10 on 29 items, total score ranged from 0-100, 0-4: indicate no problem; 5-24 a small problem; 26-49: moderate problem; 50-95: severe problem; 96-100: very severe problem
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03991897
|Contact: Sarah Thomis, MDemail@example.com|
|Contact: Christoph Matthys, PhDfirstname.lastname@example.org|
|Principal Investigator:||Sarah Thomis, MD||Universitaire Ziekenhuizen Leuven|